Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Oral Vaccine Against Sylvatic Plague Showing Significant Promise
A new oral vaccine against sylvatic plague is showing significant promise in the laboratory as a way to protect prairie dogs and may eventually protect endangered black-footed ferrets who now get the disease by eating infected prairie dogs, according to results by a USGS researcher at the USGS National Wildlife Health Center. Sylvatic plague is an infectious bacterial disease usually transmitted from animal to animal by fleas. This exotic disease is usually deadly for black-footed ferrets and their primary prey, prairie dogs, resulting in local extinctions or regional population reductions. Along with other wild rodents, prairie dogs are also considered a significant reservoir of plague for other wildlife, domestic animals, and people in the western U.S. Prevention of plague in wild rodents by immunization could reduce outbreaks of the disease in animals, thereby reducing the risk for human exposure to the disease.
generic viagra online
Impax Receives FDA Approval For Generic Precose(R) Tablets, 25 Mg, 50 Mg And 100 Mg
Impax Laboratories, Inc. (NASDAQ: IPXL) confirmed that the U.S. Food and Drug Administration (FDA) has granted approval of the Company"s Abbreviated New Drug Application (ANDA) for generic versions of Precose® Tablets (acarbose), 25 mg, 50 mg and 100 mg strengths. Precose®, a Bayer HealthCare Pharmaceuticals product, is used in the management of type two diabetes mellitus.
News of the day
Chalenges Faced By HIV Patients Living Longer Lives Due To New Therapies
New HIV therapies have prolonged lives and improved health for patients with HIV, but the treatments have also brought the longer-term effects of the disease into sharper focus.
Health Insurance

Phase II Study Of Sunitinib In Men With Advanced Prostate Cancer

UroToday.com - In the Annals of Oncology, Dr. Dror Michaelson and associates reported Phase II data on the efficacy and safety of the tyrosine kinase inhibitor sunitinib in patients with castration-resistant prostate cancer (CRPC). Sunitinib inhibits vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), both elevated in prostate cancer (CaP). Two groups of patients were studied; group A, which was chemotherapy naç¯ve and group B, which had failed docetaxel. The primary endpoint was PSA decline >50% from baseline. Secondary endpoints included objective response rate, safety, tolerability and serum biomarkers. Treatment was in 6-week cycles, consisting of 50mg daily for 4 weeks followed by 2 weeks off. Concurrent treatment with bisphosphonates was permitted. Seventeen men in each group had data available for analysis. Only one patient in group A, and one patient in group B demonstrated a >50% PSA decline. Fourteen of 34 men had some PSA decline and 8 men (34%) had a >30% PSA decline. At 12-week analysis it was noted that radiographic improvements were present in some patients who nevertheless had increasing PSA levels. Based upon not having 2 or more PSA response criteria met, the study enrollment was not continued. Adverse events were primarily grade 1 or 2 and included nausea, fatigue, anorexia, taste disturbance, vomiting, diarrhea and skin rash. Regarding biomarkers, sVEGFR2, PDGFaa, and leptin all decreased but did not correlate with PSA. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR Ann Oncol. 2009 May;20(5):913-20. doi:10.1093/annonc/mdp111 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009